What are the recommended antidepressants for treating depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Antidepressants for Treating Depression

Escitalopram and sertraline are the recommended first-line antidepressants for treating depression due to their favorable efficacy and side effect profiles. 1

First-Line Treatment Options

SSRIs (Selective Serotonin Reuptake Inhibitors)

  • Escitalopram (Lexapro)

    • Initial dose: 10 mg daily
    • Maximum dose: 20 mg daily
    • Particularly favorable side effect profile among SSRIs 1
    • Preferred for geriatric patients (start at 5 mg/day) 1
  • Sertraline (Zoloft)

    • Initial dose: 25-50 mg daily
    • Maximum dose: 200 mg daily
    • Particularly effective for depression with anxiety symptoms 1
    • Superior efficacy profile compared to fluoxetine 2
  • Other SSRIs

    • Citalopram (Celexa): 10 mg daily, maximum 40 mg daily (20 mg maximum in elderly due to QT prolongation risk) 1
    • Fluoxetine (Prozac): 10 mg daily, maximum 60 mg daily 1
    • Paroxetine: Note that it has more anticholinergic effects than other SSRIs 1

Second-Line Treatment Options

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

  • Venlafaxine

    • More effective than fluoxetine in multiple studies 2
    • Caution: May increase blood pressure at higher doses 3
  • Other SNRIs

    • Duloxetine: More balanced serotonin and norepinephrine reuptake inhibition 3
    • Milnacipran (not approved for depression in the USA) 3
    • Levomilnacipran 3

Other Antidepressant Classes

  • Mirtazapine

    • More effective than fluoxetine in some studies 2
    • Side effects include sedation and weight gain 1
  • Tricyclic Antidepressants (TCAs)

    • Use with caution due to more anticholinergic effects 1
    • Avoid in elderly patients with dementia 1

Special Considerations

Monitoring and Follow-up

  • Assess response within 1-2 weeks of starting treatment 1
  • Continue treatment for at least 4-9 months after achieving remission for first episode 1
  • Continue for at least 1 year for recurrent depression 1
  • Monitor for:
    • Suicidal thoughts (particularly in young adults 18-24) 1, 4
    • Hyponatremia
    • Changes in appetite and weight
    • Sexual dysfunction (common with SSRIs) 1

Important Precautions

  • Screen for bipolar disorder before starting antidepressants 1, 4

    • Antidepressants can trigger manic episodes in undiagnosed bipolar disorder 1
    • MAOIs and other antidepressants should never be used together due to risk of serotonin syndrome 4
  • Drug interactions

    • SSRIs may inhibit CYP2D6, affecting metabolism of other medications 5
    • Sertraline has favorable drug interaction profile compared to some other antidepressants 5
    • Avoid combining serotonergic medications due to risk of serotonin syndrome 5, 4

Common Pitfalls to Avoid

  1. Failing to screen for bipolar disorder before initiating antidepressants 1
  2. Overlooking medication interactions, especially with serotonergic agents 1
  3. Inadequate monitoring for suicidal thoughts, particularly in young adults 1
  4. Stopping treatment too soon after symptom improvement 1
  5. Not accounting for side effect profiles when selecting an antidepressant 1

Augmentation for Treatment-Resistant Depression

For patients who don't respond to first-line treatments:

  • Consider atypical antipsychotics (aripiprazole, brexpiprazole, cariprazine, quetiapine extended-release) 6
  • Weigh benefits against potential adverse events (weight gain, akathisia, tardive dyskinesia) 6

References

Guideline

Management of Anxiety and Irritability in Patients Undergoing Stressful Periods

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Fluoxetine versus other types of pharmacotherapy for depression.

The Cochrane database of systematic reviews, 2013

Research

Serotonin and Norepinephrine Reuptake Inhibitors.

Handbook of experimental pharmacology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.